Federal Cannabis Rescheduling:
What Oklahoma OMMA Businesses Need to Know

280E Relief, DEA Registration, and What Comes Next for Medical Marijuana Licensees

Updated November 4, 2026 | Reading Time: 21 minutes

On April 23, 2026, then Acting Attorney General Todd Blanche (confirmed as Attorney General in August 2026) signed a final order moving FDA-approved marijuana drug products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act. The AG’s order became effective 5 days later, when it was published in the Federal Register on April 28th. Additionally, for the first time since 1970, the federal government has now drawn a legal distinction between medical marijuana and recreational marijuana.

For Oklahoma’s more than 4,000 OMMA licensed dispensaries, growers, processors, transporters, and laboratories, this is the most consequential federal cannabis policy change since SQ788. However, it also carries significant ambiguity. This post walks through what’s currently known, what’s currently unknown, and what OMMA licensees should be doing now, as of November 2026, to position themselves under the rules as they stand.

Table of Contents

• What the April 23 Final Order Actually Did
• Section 280E Relief: The Headline Tax Change
• DEA Registration: After the 60 Day Window
• CLF’s Recommendation on DEA Registration
• Impact on Growers, Processors, Transporters, Laboratories
• Interstate Commerce: Possible, Not Definite
• What the Order Does Not Change
• Immediate Action Items for OMMA Licensees
• Frequently Asked Questions

What the April 23 Final Order Actually Did

The order is narrow in scope and broad in significance. It does not federally legalize marijuana. Recreational marijuana, unlicensed bulk marijuana, and synthetic THC remain in Schedule I. The order applies only to:

• FDA-approved drug products containing marijuana; and
• Marijuana “in any form covered by a state medical marijuana license”; which, in Oklahoma, means product produced, processed, transported, tested, and dispensed under an OMMA commercial license.

The order was issued under the Acting Attorney General’s authority at 21 U.S.C. § 811(d), which permits rescheduling outside the ordinary administrative rulemaking process when necessary to comply with U.S. obligations under the United Nations Single Convention on Narcotic Drugs. A separate administrative hearing on moving all marijuana, including recreational marijuana, to Schedule III began June 29, 2026. As of November 2026 the testimony is over, final briefs are due in early November, and the judge’s recommendation is still pending, so any change for recreational marijuana is months away at the earliest.

Opponents, including the states of Nebraska and Indiana, have asked a federal appeals court in Washington, D.C. to set the order aside. In September 2026 the court refused to pause it, so the order remains in effect while the case continues.

The full text of the DOJ Final Order is available here, and the DOJ’s accompanying press release provides additional context. OMMA’s preliminary statement is available on its news page.

Section 280E Relief: The Headline Tax Change

The single largest immediate impact for Oklahoma medical marijuana licensees is the removal of Internal Revenue Code Section 280E as a barrier to ordinary business deductions.

Section 280E disallows deductions and credits for any business “trafficking” in a Schedule I or Schedule II controlled substance. Because marijuana sat in Schedule I for over five decades, every OMMA licensee has historically been barred from deducting rent, payroll, marketing, professional fees, and most other ordinary operating expenses on federal returns. The result has been effective federal tax rates that often exceed 70% of net income.

With state-licensed medical marijuana now in Schedule III, that barrier is gone. The U.S. Department of the Treasury and IRS confirmed this in a joint announcement on April 23, 2026, stating that “rescheduling generally removes section 280E as a bar to claiming deductions and credits for businesses that as a result of the Final Order no longer traffic in Schedule I or II controlled substances under the CSA.”

The Full-Year Transition Rule

Treasury and IRS also confirmed that forthcoming guidance is expected to include a transition rule under which “rescheduling generally will be considered to first apply for a business’s full taxable year that includes the effective date of the Final Order.” For most OMMA licensees, this means 280E relief is expected to apply to the entire 2026 tax year, not merely to activity occurring on or after April 28.

This is a meaningful planning point. Operators paying quarterly estimated taxes should work with their CPAs immediately to recalculate 2026 estimates based on the assumption that ordinary deductions are now allowable for the full year. Overpayments can be substantial.

Retroactive Relief for Prior Years: Possible but Not Confirmed

The DOJ Final Order took the unusual step of encouraging the Secretary of the Treasury to consider providing “retrospective relief from Section 280E liability for taxable years in which a state licensee operated under a state medical marijuana license.”

This language is significant but isn’t a directive. Treasury operates independently of DOJ, and the IRS hasn’t yet committed to retroactive relief. The April 23 Treasury/IRS press release addressed only the forward-looking transition rule and was silent on prior years.

If retroactive relief is granted, Oklahoma medical marijuana operators could potentially file amended returns for open tax years (generally the prior three years, though longer in some circumstances) and recover substantial 280E-driven overpayments. The financial stakes are enormous, but the likelihood and scope remain unconfirmed.

DEA Registration: After the 60 Day Window

On April 29, 2026, the DEA opened its Medical Marijuana Dispensary Registration Portal. OMMA’s release announcing the portal is available here.

The expedited window ran from April 28 through June 26, 2026. DEA has said it aims to process timely applications within six months, and timely applicants may keep operating under their state licenses while they wait. Oklahoma filed more timely applications than any other state. DEA issued its first registrations on October 30, 2026, to dispensaries in seven other states, and manufacturer and distributor applications are still under review.

How the DEA Application Works

The online application is built for state licensees. It covers the business, the activities and substances involved, the state license, the owners’ history, and compliance matters such as suppliers and operating procedures, and the dispensary application carries a $794 fee. Manufacturer, distributor, and lab registrations carry higher DEA fees.

The application is intentionally streamlined for state-licensed applicants. Under the Final Order, the DEA must accept an applicant’s existing state medical marijuana license as “conclusive evidence” that the applicant is authorized to operate under state law. The DEA may also accept compliance with state security, labeling, packaging, and disposal standards in lieu of separate federal requirements, subject to the warning label required by 21 U.S.C. § 825(c).

Pros and Cons of DEA Registration

OMMA hasn’t taken a formal position on whether licensees should register. The April 28 corrected release is explicit that “dispensaries choosing not to participate may continue to operate in accordance with the existing regulatory framework in Oklahoma and may still be eligible for potential tax breaks.” That language reflects the current state of the rules, not a recommendation in either direction.

Arguments in favor of registering:

• Expedited review for timely applicants. Applications filed by June 26, 2026 are targeted for processing within six months, and the applicant can keep operating under state authority during review. Late filers don’t get those protections.
• Federal recognition as a legitimate medical practitioner. The DOJ Final Order treats DEA-registered state licensees as the federally lawful supply chain for medical marijuana. Registration provides an unambiguous federal status that may matter for banking relationships, payment processing, federal contracting, insurance, and access to the federal regulatory benefits being developed.
• Optionality on interstate commerce. The Final Order amends 21 CFR § 1312.30 to bring state-licensed medical marijuana within the import/export permit framework that already governs other Schedule III substances. Whether and how interstate commerce will actually open is a separate question, but only DEA registrants will be positioned to participate when it does.
• Insulation against future guidance. Several open questions (including how Treasury, FinCEN, the FDA, and SBA will treat state-licensed cannabis operators going forward) may resolve in ways that condition certain benefits on DEA registration. CANNRA’s overview notes that “more details are needed about how DEA and states will communicate and coordinate.” The cautious posture is to register now and preserve full optionality.

Arguments against registering, or for waiting:

• Federal compliance overlay. Registration brings the licensee under DEA inspection authority, federal record-keeping obligations (a two-year minimum), and federal reporting requirements. The DEA has indicated it will accept state records to the maximum extent permissible, but the federal layer is real.
• Direct cost. The $794 application fee is the published initial cost. Annual renewal fees and the standard DEA Schedule III fee structure for manufacturers, distributors, and dispensers will apply in addition. Final, published Oklahoma-specific fee details should be confirmed via the DEA portal at the time of filing.
• Single Convention purchase-and-resale mechanism. The Final Order requires the DEA to operate a nominal purchase-and-resale system for marijuana crops to satisfy treaty obligations. Registered manufacturers must store crops in a facility to which DEA maintains access until the transaction is complete. The operational impact of this requirement isn’t yet clear.
• State-license linkage risk. A DEA registration auto-suspends, is revoked, or expires whenever the underlying state license does. This is largely a non-issue for compliant operators but does mean that any OMMA enforcement action carries an automatic federal consequence.

CLF’s Recommendation on DEA Registration

Impact on Growers, Processors, Transporters, Laboratories

The DEA’s April 29 portal launch and OMMA’s April 28 release applied at first only to dispensaries. OMMA has stated that “OMMA will share updates for other commercial license types and patients as more guidance becomes available.”

The DOJ Final Order itself, however, contemplates DEA registration pathways for manufacturers (which encompasses Oklahoma growers and processors) and distributors, in addition to dispensers. The CANNRA overview cited by OMMA confirms that “manufacturers, distributors, and dispensers in state-regulated programs who want to participate will need to register with the DEA.” DEA now has registration forms and fees for manufacturers, distributors, and testing labs, and many Oklahoma growers and processors applied during the window.

Growers, processors, transporters, and testing laboratories should monitor OMMA’s news page closely and talk with counsel about where their applications stand. Manufacturer and distributor applications filed during the window are still under review as of November 2026, because they require inspections and quota decisions.

Interstate Commerce: Possible, Not Definite

One of the most-asked questions among Oklahoma operators is whether rescheduling permits shipping product across state lines. The short answer remains no, with important nuances.

The Final Order does not create immediate interstate commerce in medical marijuana. State-licensed medical marijuana, although now in Schedule III, remains subject to import and export permit requirements under 21 CFR § 1312.30, which the order specifically amends to add medical marijuana to the list of nonnarcotic Schedule III to V substances subject to those requirements. Translation: even between two states with reciprocal medical programs, an interstate shipment requires a federal permit that hasn’t yet been operationalized.

The CANNRA overview acknowledges that “interstate commerce and trade may occur” and that the order “outlines import and export processes that could be used for commerce across governments,” but the practical infrastructure isn’t yet established.

What the Order Does Not Change

Several important categories are explicitly outside the Final Order’s reach:

• Recreational marijuana remains Schedule I. (Oklahoma has no adult-use program, so this distinction is largely academic for in-state operators but matters for any MSO with operations in adult-use states.)
• Unlicensed bulk marijuana, marijuana extracts not yet incorporated into FDA-approved drugs, and synthetic THC remain Schedule I.
• Federal criminal penalties for marijuana are unchanged, and existing federal marijuana convictions are not expunged.
• FDA jurisdiction over food and dietary supplement claims is unchanged. The Federal Food, Drug, and Cosmetic Act continues to apply, and FDA hasn’t established a safety standard for cannabinoids in food outside of approved drugs.
• Personal patient travel across state lines remains legally risky. An OMMA patient license is not a federal prescription, and the rescheduling does not create state-to-state reciprocity. TSA still refers marijuana discoveries to local law enforcement.
• Hemp (defined separately and excluded from the federal definition of marijuana) is unaffected, although most of the change to the federal hemp definition, which limits hemp to industrial and low THC products, has been pushed back to December 11, 2026.

Immediate Action Items for Oklahoma OMMA Licensees

1. Contact CLF. The November 29, 2026 DEA supply chain deadline and the January 1, 2027 state enforcement date for manufacturers and distributors are coming up fast, and the 2026 tax year is closing. Protective refund claims for prior years also require deliberate filing decisions. Schedule a consultation to discuss how rescheduling affects your specific operation.
2. Audit 2026 estimated tax payments immediately. If you’re a calendar-year filer, the expected full-year transition rule means 280E should not apply to medical activity for any portion of 2026. Coordinate with your CPA on your fourth quarter estimate and year end planning. The IRS has put 280E guidance on its priority list for the year ahead but hasn’t issued it as of November 2026, so the full year transition rule is still expected rather than final. Overpayment is the default risk for operators who keep paying as if 280E still applies.
3. Check your supply chain before November 29, 2026. If you’re a timely applicant, confirm that every grower, processor, and transporter you deal with is a DEA registrant or timely applicant, and keep records of how you checked. If you aren’t, talk with counsel about whether to apply now.
4. Discuss protective refund claims with tax counsel. If retrospective Section 280E relief materializes, the recovery potential is substantial. Statutes of limitations on refund claims continue to run regardless of whether IRS guidance arrives. Operators with material 280E exposure in prior years should ask which years are still open and whether to file protective claims to preserve their position.
5. Monitor OMMA, DEA, Treasury, and FinCEN releases. Implementation guidance is expected on a rolling basis. OMMA’s news page, the Treasury press release page, and the DOJ Office of Public Affairs page are the primary authoritative channels.
6. Do not assume interstate commerce is open. Until DEA establishes the operational permit infrastructure for medical marijuana imports and exports, shipping product across state lines remains a federal violation, even between two medical-program states.

🌿 Protect Your OMMA Business Under the New Federal Rules

Federal cannabis rescheduling presents both opportunity and risk for every Oklahoma OMMA licensee.

The DEA supply chain deadline, Section 280E tax planning, and protective refund claims all carry near term decision points with material financial consequences. Cantrell Law Firm advises Oklahoma cannabis operators on entity structure, federal and state regulatory compliance, tax positioning, and transactional matters arising from the new federal framework. Our Oklahoma cannabis business attorneys are tracking these changes for OMMA licensees and can help you plan for each scenario.

• DEA registration and supply chain compliance
• Section 280E tax positioning and protective refund claim coordination
• OMMA compliance and license maintenance
• Vertically integrated operator structuring
• Banking, contracting, and transactional support for cannabis operators

Schedule Your Free Consultation

Free initial consultation • Prompt response • Former business owners

Frequently Asked Questions

• Is my OMMA license still valid after rescheduling?

  Yes. OMMA continues to operate under Oklahoma law. The federal rescheduling does not affect OMMA’s authority to issue, renew, suspend, or revoke commercial or patient licenses. Your OMMA license remains the foundation of your authorization to operate.

• Do I have to register with the DEA?

  It depends on your license type. DEA hasn’t made registration mandatory for every state licensee, and OMMA says state licensing rules haven’t changed. But the Oklahoma Bureau of Narcotics has told registrants that manufacture or distribute medical marijuana products, which generally means growers and processors, that they’ll need DEA registration, and it has said it won’t take action against them before January 1, 2027. DEA’s rules also make it hard for unregistered businesses to sell to registered ones. For most Oklahoma operators, registration is now a practical necessity. Talk with counsel about your specific licenses.

• Will I lose Section 280E relief if I do not register with the DEA?

  Based on currently available guidance, no. OMMA’s April 28, 2026 corrected notice expressly states that the 280E tax burden is removed for state medical marijuana licensed businesses regardless of whether they pursue a DEA license. Future Treasury or IRS guidance could still condition certain tax benefits on DEA registration. And handling a Schedule III substance without DEA registration carries its own federal risk, so tax relief and registration should be looked at together.

• Can I file amended returns now to recover prior-year 280E payments?

  The DOJ Final Order encourages the US Treasury to provide retrospective relief. The IRS hasn’t yet committed to retroactive relief or established an amendment procedure. Operators with material prior-year 280E exposure should consult tax counsel about filing protective claims to preserve their position while guidance develops.

• Can I ship product to another medical state now?

  No. Interstate movement of medical marijuana remains subject to federal import and export permit requirements under 21 CFR § 1312.30, and the operational infrastructure for those permits hasn’t yet been established by the DEA. Shipping product across state lines remains a federal violation at this time.

• What’s happening with the broader DEA rescheduling hearing?

  The hearing on moving all marijuana to Schedule III ran from June 29 to July 15, 2026. It was paused in late September over a new GAO report, and final briefs on that report are due November 5, 2026. The judge will then make a recommendation, and DEA and the Attorney General would still need to issue a final rule. As of November 2026, recreational marijuana remains in Schedule I.

• What if I hold multiple OMMA license types (for example, vertically integrated grower-processor-dispensary)?

  The DOJ Final Order contemplates separate DEA registrations for manufacturer (grower/processor), distributor, and dispenser activities. Vertically integrated operators are likely to need multiple federal registrations, and each registration category carries its own DEA fee.

• Does rescheduling change OMMA’s rules, fees, or inspections?

  Not directly. OMMA continues to administer Oklahoma’s medical marijuana program under state law. OMMA has indicated it views rescheduling as supportive of its compliance and patient-safety mission, but it hasn’t announced changes to state licensing fees, rules, or inspection protocols as a result of the federal action. Separately, a 2026 Oklahoma law extended the freeze on new dispensary, processor, and grower licenses to August 1, 2028 and tightened the rules for transferring a license.

• Does this rescheduling affect my OMMA patient license or my ability to purchase medical marijuana?

  No. The rescheduling does not change patient licensing, purchase limits, or the in-state dispensary experience for Oklahoma patients. Patients should not assume the rescheduling provides any new federal protections for personal possession, transport across state lines, employment, or firearms-related matters.

• Does federal rescheduling make marijuana legal under federal law?

  No. The April 2026 order moved FDA approved marijuana drug products and marijuana covered by a state medical marijuana license, which in Oklahoma means product handled under an OMMA commercial license, to Schedule III, but it did not federally legalize marijuana. Recreational marijuana, unlicensed bulk marijuana, and synthetic THC remain in Schedule I, and federal criminal penalties for marijuana are unchanged. How the change affects your operation depends on your license types and tax position, so talk with counsel before you rely on it.

---

Disclaimer: This article provides general information about federal cannabis rescheduling and the Oklahoma medical marijuana program and should not be considered legal or tax advice. Federal cannabis policy is rapidly evolving, and the information above is current only as of the update date and is subject to change as additional guidance is issued by federal and state agencies. The discussion of Section 280E and related tax matters reflects publicly available agency announcements and is not a substitute for individualized advice from a qualified tax professional. No attorney-client relationship is created by reading this post. Readers should consult licensed legal and tax counsel before taking action on any of the matters discussed.

About Cantrell Law Firm: We are Oklahoma business attorneys who help entrepreneurs and growing companies (including Oklahoma medical marijuana operators) build practical legal foundations for long-term success. Our approach combines deep technical knowledge with real-world business experience to help clients navigate complex compliance landscapes while staying focused on running their businesses. Contact us to discuss your cannabis compliance and business law needs.